GlobeNewsWire
13 Aug 2026, 12:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Biofrontera has a PDUFA date in late September 2026 for Ameluz in the treatment of superficial basal cell carcinoma (sBCC). — FDA approval for a cancerous tumor indication would represent a major expansion of the addressable market and a first-of-its-kind PDT approval in the US.
+0.80The company reported a 32.9% year-over-year increase in Q2 net product revenue to $12.0 million. — Strong top-line growth and accelerating reorders indicate increasing commercial traction for the core product.
+0.60Adjusted EBITDA improved significantly to nearly breakeven at $(0.2) million, compared to a $(5.1) million loss in the prior-year quarter. — Rapid narrowing of losses and a path to cash flow breakeven in 2026 reduces the immediate need for dilutive financing.
+0.50Continue reading
6 related stories
Search tags
An International Trade Commission (ITC) exclusion order took effect July 7, 2026, affecting the sale of the RhodoLED XL lamp. — Regulatory restrictions on hardware sales create operational risk, although the company claims limited impact on full-year revenue.
-0.40Gross margin improved by approximately 920 basis points year-over-year to 80%. — Significant margin expansion suggests a more efficient cost structure and improved profitability per unit sold.
+0.30Which stocks this story touches
The company reported strong revenue growth, improved gross margins, and narrowed net losses in its strongest operating period to date.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
24m ago
